<DOC>
	<DOCNO>NCT01581463</DOCNO>
	<brief_summary>Liothyronine indicate treatment primary hypothyroidism . Between 6 10 Million United States 80 Million patient world-wide hypothyroid , usually result autoimmune thyroiditis call Hashimoto 's Disease . Hypothyroid symptom result low level thyroid hormone ( T4 T3 ) blood due inadequate thyroid hormone production thyroid gland . Every tissue body thyroid hormone target hypothyroid symptom debilitate . BCT303 utilizes Liothyronine , Sodium active ingredient , Liothyronine salt utilize active ingredient currently market product . The current `` gold standard '' treatment hypothyroidism product contain Levothyroxine ( T4 ) . T4 known pro-hormone , convert active hormone T3 deiodinases various tissue . Patients Levothyroxine therapy alone occasionally euthyroid measure clinical presentation , condition hypothesize result low level T3 inadequate T4 T3 conversion . In addition , efficiency conversion T4 T3 variable dependent patho-physiologic state patient . BCT303 contain Liothyronine , Sodium active ingredient . This product patent formulation granulation procedure solve multiple clinical stability problem associate T3-based product . Thus , BCT303 design : 1 . Increased shelf stability ensure maintenance claim dosage . 2 . A sustained-release profile minimize side effect associate spike serum T3 level . 3 . Uniformity dose production batch tablet .</brief_summary>
	<brief_title>A Study Sustained-Release Liothyronine Sodium ( T3 ) Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy adult Must able swallow tablet Hypothyroid Disease Pregnant Females</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>pharmacokinetics oral T3</keyword>
</DOC>